Curcumin therapy effective for non-alcoholic fatty liver disease

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-06-15 05:30 GMT   |   Update On 2023-06-15 08:55 GMT
Advertisement

A new study by Zahra Safari and team showed that patients with non-alcoholic fatty liver disease (NAFLD) may benefit from the daily use of curcumin when taking 250 mg. The findings of this study were published in Frontiers in Nutrition.

The most prevalent kind of liver disease is non-alcoholic fatty liver disease. A natural polyphenol called curcumin may be beneficial in treating steatohepatitis and liver steatosis. The current study aims to assess the effects of phytosomal curcumin on individuals with non-alcoholic fatty livers' lipid profiles, fasting blood sugar, liver enzymes, anthropometric indices, fibrosis, and steatosis. The rhizome of turmeric (Curcuma Longa) contains active ingredients known as curcuminoids, of which curcumin is the most notable. Turmeric has shown to have strong antioxidant, anti-inflammatory, and antifibrotic qualities as well as insulin sensitizing effects in in vitro and animal investigations. As a result, it may show potential in the treatment of NAFLD patients.

Advertisement

The subjects had a 12-week follow-up after being randomly assigned to receive curcumin-phosphatidylserine phytosomal or a placebo. At the start and conclusion of the clinical study, information on anthropometric indices, lipid profiles, blood glucose, blood pressure, liver enzymes, hepatic steatosis, and fibrosis were gathered.

The key findings of this study were:

1. When compared to the placebo group, a 12-week supplementation regimen with phytosomal curcumin substantially decreased fibrosis and steatosis (p < 0.05).

2. In comparison to the placebo group, phytosomal curcumin significantly decreased blood pressure and waist circumference (p < 0.05).

3. Regarding changes in weight, body mass index, liver enzymes, fasting blood glucose, and lipid profile, there was no discernible difference between the phytosomal curcumin and placebo groups.

Reference:

Safari, Z., Bagherniya, M., Khoram, Z., Ebrahimi Varzaneh, A., Heidari, Z., Sahebkar, A., & Askari, G. (2023). The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers. In Frontiers in Nutrition (Vol. 10). Frontiers Media SA. https://doi.org/10.3389/fnut.2023.1163950

Tags:    
Article Source : Frontiers in Nutrition

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News